Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp190 | Pituitary / Growth Hormone ' IGF Axis | ECE2018

Insulin sensitivity improves after disease control in acromegaly irrespective of treatment modality and despite an increase in intrahepatic lipid content: data from an investigator-initiated prospective trial

Arlien-Soborg Mai C , Dal Jakob , Madsen Michael , Hogild Morten , Jessen Niels , Jorgensen Jens Otto Lunde

Background: Active acromegaly induces insulin resistance despite a lean phenotype, both of which reverse by curative surgery. The impact of somatostatin analogue treatment on insulin sensitivity is less certain and may be offset by its anti-lipogenic effects.Aim: To study insulin sensitivity, body composition and extopic lipid content in newly diagnosed patients with acromegaly before and ≥6 months after successful surgical or medical treatment.</p...

ea0099p344 | Pituitary and Neuroendocrinology | ECE2024

Growth hormone potently stimulates fibroblast activation protein activity and collagen turnover – a prospective study in newly diagnosed patients with acromegaly before and after treatment

Baek Amanda , Kathrine Pedersen Anne , Arlien-Soborg Mai , Jessen Niels , Bjerre Mette , Otto Jorgensen Jens

Background: GH potently stimulates collagen turnover which underlies its anabolic effects on bone in children, whereas it may promote fibrosis in adults. Fibroblast activation protein-α (FAPα) is involved in collagen turnover by its collagen-cleaving and fibroblast-stimulating activity, which predominantly is expressed in association with fibrosis. FAPα also cleaves and inactivates fibroblast growth factor 21 (FGF21), a multi-faceted metabolic hormone. We have p...

ea0090p684 | Pituitary and Neuroendocrinology | ECE2023

Fibroblast Activation Protein in Patients with Growth Hormone Deficiency and Acromegaly: Before and After Treatment

Baek Amanda , Arlien-Soborg Mai C. , Kathrine Nissen Pedersen Anne , Jessen Niels , Bjerre Mette , Otto Lunde Jorgensen Jens

Background: It is well-known that growth hormone (GH) potently stimulates collagen turnover and it is associated with fibrosis in several tissues, but the mechanisms involved in GH-stimulated fibrosis are poorly elucidated. Fibroblast activation protein-α (FAPα) is an enzyme that can cleave collagens and is expressed almost only under pathological conditions such as fibrosis. FAPα also cleaves and inactivates fibroblast growth factor 21 (FGF21), which is a circu...

ea0063oc3.4 | Cushing's and acromegaly | ECE2019

Restoration of basal glucose turnover after disease control in acromegaly depends on treatment modality: a prospective, investigator-initiated trial

Arlien-Soborg Mai C , Dal Jakob , Madsen Michael , Hogild Morten , Hjelholt Astrid , Jessen Niels , Moller Niels , Otto Lunde Jorgensen Jens

Background: Growth Hormone (GH) reversibly suppresses insulin-stimulated glucose uptake in skeletal muscle, but less is known about GH effects on glucose metabolism in the basal state. Somatostatin suppresses GH as well as insulin, and may also exert direct effects in skeletal muscle. This may have therapeutic implications in the treatment of acromegalic patients with a somatostatin analogue (SA).Aim: To study basal and insulin-stimulated glucose metabol...

ea0049gp17 | Adrenal 2 | ECE2017

Hypercortisolism is prevalent in newly diagnosed type 2 diabetes: a prospective study of 384 consecutive patients

Steffensen Charlotte , Dekkers Olaf M , Lyhne Johanne , Poulsen Per L , Rungby Jorgen , Sorensen Henrik T , Jorgensen Jens Otto L

Background: Cross-sectional studies in small and selected populations indicate a relatively high prevalence of incipient and/or subclinical Cushing’s syndrome (CS) in patients with type 2 diabetes (T2D), which could have therapeutic implications.Aim: To estimate the prevalence of CS in a large, unselected cohort of recently diagnosed T2D patients.Methods: A total of 384 consecutive out – patients with T2D diagnosed after ...

ea0041ep25 | Adrenal cortex (to include Cushing's) | ECE2016

Low positive predictive value of midnight salivary cortisol measurement to detect hypercortisolism in type 2 diabetes

Steffensen Charlotte , Thomsen Henrik Holm , Dekkers Olaf M , Christiansen Jens S , Rungby Jorgen , Jorgensen Jens Otto L

Background: Hypercortisolism is prevalent in type 2 diabetes (T2D), but analytical and functional uncertainties prevail. Measurement of salivary cortisol is considered an expedient screening method for hypercortisolism, but its usefulness in the context of T2D is uncertain.Aim: To compare late night salivary cortisol (LNSC) with the 1 mg overnight dexamethasone suppression test (DST), which was considered ‘reference standard’, in T2D.<p cla...

ea0070aep777 | Pituitary and Neuroendocrinology | ECE2020

Acromegaly is associated with reduced socioeconomic status and more so in female patients: A nationwide population-based study

Dal Jakob , Nielsen Eigil H , Feldt-Rasmussen Ulla , Andersen Marianne , Feltoft Claus , Vestergaard Peter , Stochholm Kirstine , Otto Jorgensen Jens

Context: Acromegaly is a rare and insidious disease associated with severe somatic morbidity but data on socioeconomic status are scarce.Objective: To study the socioeconomic status in acromegaly in a population based, nationwide follow-up study.Patients and Methods: All incident cases of acromegaly (n = 576) during the period 1997–2010 were included, representing 10.116 years at risk. For every patient, 100 pers...

ea0022p229 | Clinical case reports and clinical practice | ECE2010

Dose of growth hormone (GH) and not IGFI level at treatment start influences treatment outcome in GH deficient adults (GHDA): Data from the NordiNet International Outcome Study (IOS)

Jorgensen Jens Otto L , Weber Matthias M , Hoybye Charlotte , Pedersen Birgitte T , Rakov Viatcheslav , Christiansen Jens Sandahl

Background: Serum IGFI measurements are used during GH replacement in GHDA for titration of the GH dose, to monitor compliance and to avoid overdosing, but it is uncertain if pretreatment IGFI is a determinant of the GH dose or the response to GH treatment.Methods: Data from the NordiNet IOS have been analyzed to determine pretreatment serum IGFI concentrations in GHDA and to analyze if they influence the GH starting dose and/or the therapeutic response ...

ea0022p264 | Developmental endocrinology | ECE2010

Baseline characteristics and serum IGF1 levels in GH deficient (GHD) patients treated in the transition phase from adolescence into adulthood: data from the NordiNet International Outcome Study (IOS)

Weber Matthias M , Blankenstein Oliver , Jorgensen Jens Otto L , Pedersen Birgitte T , Rakov Viatcheslav , Christiansen Jens Sandahl

Background: Data from several clinical studies have demonstrated the benefit of GH treatment in relation to bone mineral density and body composition in young adults who received GH treatment in childhood due to GHD1–3. There are recommendations to use a higher GH dose in the transition phase compared to the GH dose required during adulthood to mimic the endogenous GH secretion4,5.Methods: Data from NordiNet IOS have been analy...

ea0016p740 | Thyroid | ECE2008

Serum ghrelin levels are increased in hypothyroid patient and become normalized after L-thyroxin treatment

Gjedde Signe , Vestergaard Esben Thyssen , Gormsen Lars Christian , Riis Anne Lene , Rungby Jorgen , Moller Niels , Weeke Jorgen , Jorgensen Jens Otto

Context: An interaction between gut-derived ghrelin, which is implicated in the regulation of short- and long-term energy balance, and thyroid function has previously been reported in patients with hyperthyroidism, in whom ghrelin levels are reversibly suppressed. In the present study, we measured total serum ghrelin levels and pertinent metabolic indices in hypothyroid patients before end after L-thyroxin replacement.Patients and methods:...